Radiology Case Reports (Jul 2024)

A case of pelvic EWSR1-PATZ1 fusion sarcoma treated with carbon ion radiotherapy

  • Toshinari Yagi, MD,
  • Osamu Suzuki, PhD,
  • Haruki Matsuoka, MD,
  • Kei Shinyashiki, MD,
  • Toru Wakamatsu, MD, PhD,
  • Hironari Tamiya, MD, PhD,
  • Rie Suzuki, MD,
  • Shigeki Kakunaga, MD, PhD,
  • Satoshi Takenaka, MD, PhD,
  • Yoshiko Hashii, MD, PhD,
  • Ken-ichi Yoshida, MD, PhD,
  • Katsuyuki Nakanishi, MD, PhD

Journal volume & issue
Vol. 19, no. 7
pp. 2674 – 2678

Abstract

Read online

EWSR1-PATZ1 fusion sarcoma is a type of round-cell sarcoma with EWSR1-non-EST fusion that was newly categorized in the 2020 World Health Organization classification of soft tissue and bone tumors. In general, local disease is managed via surgical resection; however, at present, there is no standard therapy for locally advanced or metastatic disease. Here, we report our experience with a middle-aged male patient with pelvic EWSR1-PATZ1 fusion sarcoma who was treated with carbon ion radiotherapy and maintained stable disease for 13 months. The patient's clinical course suggests that carbon ion radiotherapy may be effective in patients with locally advanced EWSR1-PATZ1 fusion sarcoma.

Keywords